tenofovir
HIV Infection
Giovanni Di PerriSmall moleculePhase 4 / ApprovedDormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 89/ 100
Competitive context
62 Active assets in the HIV Infection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Raltegravir Helsinki University Central Hospital | Phase 4 | A |
ZIDOVUDINE International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Phase 4 | BBB |
Efavirenz The Cleveland Clinic | Phase 4 | BBB |
Abacavir Germans Trias i Pujol Hospital | Phase 4 | BBB |
Dolutegravir Instituto Mexicano del Seguro Social | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
tenofovir is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →